Mattson Financial Services LLC Has $1.64 Million Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Mattson Financial Services LLC lifted its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 20.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 21,119 shares of the medical device company's stock after purchasing an additional 3,584 shares during the period. Mattson Financial Services LLC's holdings in DexCom were worth $1,642,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Private Trust Co. NA grew its holdings in shares of DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock worth $26,000 after purchasing an additional 245 shares during the last quarter. Optiver Holding B.V. acquired a new stake in DexCom in the fourth quarter valued at about $33,000. TD Private Client Wealth LLC lifted its position in shares of DexCom by 62.8% during the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after acquiring an additional 167 shares during the period. Larson Financial Group LLC lifted its position in shares of DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after acquiring an additional 137 shares during the period. Finally, Heck Capital Advisors LLC acquired a new stake in shares of DexCom during the 4th quarter valued at approximately $38,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Stock Up 1.3%

NASDAQ:DXCM traded up $1.10 during trading hours on Friday, hitting $85.96. 4,257,051 shares of the stock traded hands, compared to its average volume of 4,370,189. The firm has a 50 day moving average price of $74.42 and a 200 day moving average price of $78.57. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $121.47. The firm has a market cap of $33.71 billion, a price-to-earnings ratio of 60.11, a PEG ratio of 2.30 and a beta of 1.43.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a return on equity of 30.14% and a net margin of 14.29%. The company had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.02 billion. During the same period last year, the company posted $0.32 earnings per share. The company's revenue was up 12.5% compared to the same quarter last year. Equities research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the stock. Canaccord Genuity Group raised their price objective on shares of DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Robert W. Baird reduced their target price on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a report on Friday, May 2nd. Redburn Atlantic upgraded shares of DexCom from a "neutral" rating to a "buy" rating and boosted their price objective for the stock from $85.00 to $115.00 in a report on Monday, February 3rd. Mizuho assumed coverage on shares of DexCom in a report on Thursday, April 10th. They issued an "outperform" rating and a $85.00 price objective on the stock. Finally, Cfra Research raised shares of DexCom to a "hold" rating in a research report on Friday, March 21st. Five investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $98.32.

Insider Activity

In other news, EVP Jereme M. Sylvain sold 7,000 shares of DexCom stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $73.83, for a total value of $516,810.00. Following the completion of the transaction, the executive vice president now owns 135,482 shares in the company, valued at approximately $10,002,636.06. The trade was a 4.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Jacob Steven Leach sold 14,076 shares of DexCom stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $990,668.88. Following the completion of the transaction, the chief operating officer now owns 313,497 shares of the company's stock, valued at $22,063,918.86. This trade represents a 4.30% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 83,110 shares of company stock valued at $6,103,505. 0.32% of the stock is owned by insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.